Loading organizations...

§ Private Profile · San Diego, CA, USA
Clinical-stage biopharmaceutical company developing small-molecule drugs for metabolic diseases, Prader-Willi syndrome, and inflammation.
Aardvark has raised $126.0M across 4 funding rounds.
Key people at Aardvark.
Aardvark was founded by Max Ventilla (Founder and Zoo Director).
Aardvark has raised $126.0M in total across 4 funding rounds.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for metabolic and inflammatory diseases, based in San Diego, California. The organization focuses on compounds that target extraoral bitter taste receptors to alleviate hunger-associated conditions, with its lead candidate, ARD-101, receiving FDA Orphan Drug Designation for Prader-Willi syndrome. Operating with approximately 40 employees, the enterprise has secured over $110 million in total funding to advance its clinical pipeline toward commercialization. This capitalization includes an $85 million Series C financing round backed by institutional investors such as Decheng Capital, Cormorant Asset Management, and Vickers Venture Partners. The company intends to utilize this capital to complete ongoing clinical trials and prepare for a planned FDA approval filing in 2026. Aardvark Therapeutics was founded in 2017 by Dr. Tien Lee.
Aardvark (Aardvark Technologies) is a Lithuania‑based software company that builds high‑performance omnichannel betting and gaming platforms (marketed under Adv.bet) used by bookmakers and operators across Africa, Central America and parts of Europe, with a focus on reliability in low‑infrastructure environments and retail + online integration[1][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick factual notes: company registration records list a Lithuanian entity (Aardvark Technologies UAB) with public registry details and ~70–100 employees reported across business directories, and the firm markets its Adv.bet product and related offerings on its site and industry expos[2][6][3][4].
Aardvark has raised $126.0M across 4 funding rounds. Most recently, it raised $85.0M Aardvark Therapeutics - Series C in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 9, 2024 | $85M Series C | Victor Tong | Cantor Fitzgerald, Cormorant Asset Management, Theresa Strong, Laurion Capital Management, LG Technology Ventures, Silver ARC Private Capital, Surveyor Capital, SymBiosis, Tetragon Financial Group, Stacy Ward, Vickers Venture Partners, Walleye Capital | Announced |
| Aug 6, 2021 | $29M Series B | Sorrento Therapeutics | BNH Investment, Foundation For Prader Willi Research, Korea Omega Investment, Premier Partners, Vickers Venture Partners | Announced |
| Jul 1, 2021 | $7M Series B | — | Aisling Capital, Endeavor Venture Funds, OrbiMed, James Barrett | Announced |
| Sep 1, 2008 | $5M Series A | — | Harrison Metal, Lobby Capital | Announced |
Key people at Aardvark.
Aardvark was founded by Max Ventilla (Founder and Zoo Director).
Aardvark has raised $126.0M in total across 4 funding rounds.
Aardvark's investors include Victor Tong, Cantor Fitzgerald, Cormorant Asset Management, Theresa Strong, Laurion Capital Management, LG Technology Ventures, Silver Arc Private Capital, Surveyor Capital, SymBiosis, Tetragon Financial Group, Stacy Ward, Vickers Venture Partners.